CODX
Another Ebola breadcrumb
Co-Diagnostics is back in the Ebola chat, this time through its joint venture CoSara, which is providing Ebola test kits for analytical studies. That’s not the same as a shiny approval stamp, but it is the kind of behind-the-scenes work that can matter when a diagnostics company is trying to prove its tech is more than a lab demo.
Why investors should care
For a company like CODX, progress often looks less like fireworks and more like a stack of incremental steps. Supplying kits for analytical studies suggests the program is moving forward in the validation process, which can help build credibility with potential partners, labs, and buyers.
The fine print
This doesn’t automatically mean a revenue home run is around the corner. But it does keep the Ebola program alive, and for small-cap diagnostics names, keeping the story alive is half the battle.
Big picture: if Co-Diagnostics can keep translating technical milestones into real-world testing use cases, the market may start treating it less like a science project and more like a business.